Skip to main content
. 2022 Jul 4;12:950266. doi: 10.3389/fonc.2022.950266

Table 2.

Best tumor response of the 114 patients.

Variable Total (n = 114)
Best overall response by mRECIST version 1.1, n (%)
 Complete response 9 (7.9)
 Partial response 70 (61.4)
 Stable disease 13 (11.4)
 Progressive disease 22 (19.3)
 Objective response rate, n (%) 79 (69.3)
 Disease control rate, n (%) 92 (80.7)

mRECIST, modified Response Evaluation Criteria in Solid Tumors 1.1.